Trial Profile

Post-Marketing Surveillance (Usage Results Study) of Ixazomib Citrate in Patients With Multiple Myeloma in South Korea

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ixazomib (Primary)
Indications Multiple myeloma
Focus Adverse reactions
Sponsors Takeda

Most Recent Events

24 Jul 2024 Status changed from recruiting to completed.
15 Jun 2022 Planned End Date changed from 27 Sep 2023 to 27 Jun 2024.
15 Jun 2022 Planned primary completion date changed from 30 Jul 2023 to 27 Jun 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com